TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:55
Quince Therapeutics Inc. ( QNCX ) https://www.quincetx.com
1.13USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-25.17%
QNCX
SPY
32.74%
-96.64%
QNCX
SPY
92.93%
QNCX
0.00%
SPY
224.41%
QNCX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
43.29
-18.31
0.07
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.53
0.00
0.52
-43.12
0.00
0.97
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-55.14
-26.50
0.00
Other Earnings and Cash Flow Stats:
Quince Therapeutics Inc. ( QNCX ) Net Income TTM ($MM) is -31.64
Quince Therapeutics Inc. ( QNCX ) Operating Income TTM ($MM) is -32.99
Quince Therapeutics Inc. ( QNCX ) Owners' Earnings Annual ($MM) is 0.00
Quince Therapeutics Inc. ( QNCX ) Current Price to Owners' Earnings ratio is 0.00
Quince Therapeutics Inc. ( QNCX ) EBITDA TTM ($MM) is -7.66
Quince Therapeutics Inc. ( QNCX ) EBITDA Margin is 0.00%
Capital Allocation:
Quince Therapeutics Inc. ( QNCX ) has paid 0.00 dividends per share and bought back -2.576506 million shares in the past 12 months
Quince Therapeutics Inc. ( QNCX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Quince Therapeutics Inc. ( QNCX ) Interest-bearing Debt ($MM) as of last quarter is 0
Quince Therapeutics Inc. ( QNCX ) Annual Working Capital Investments ($MM) are -110
Quince Therapeutics Inc. ( QNCX ) Book Value ($MM) as of last quarter is 83
Quince Therapeutics Inc. ( QNCX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Quince Therapeutics Inc. ( QNCX ) has 21 million in cash on hand as of last quarter
Quince Therapeutics Inc. ( QNCX ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Quince Therapeutics Inc. ( QNCX ) has 36 common shares outstanding as of last quarter
Quince Therapeutics Inc. ( QNCX ) has 0 million USD of preferred stock value
Academic Scores:
Quince Therapeutics Inc. ( QNCX ) Altman Z-Score is 6.41 as of last quarter
Quince Therapeutics Inc. ( QNCX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Quince Therapeutics Inc. ( QNCX ) largest shareholder is COHEN LAWRENCE B owning 11126 shares at 0.01 ($MM) value
David Lamond(an insider) Bought 22627 shares of Quince Therapeutics Inc. ( QNCX ) for the amount of $23532.08 on 2023-12-14
17.73% of Quince Therapeutics Inc. ( QNCX ) is held by insiders, and 17.55% is held by institutions
Quince Therapeutics Inc. ( QNCX ) went public on 2019-05-09
Other Quince Therapeutics Inc. ( QNCX ) financial metrics:
FCF:-21.38
Unlevered Free Cash Flow:92.58
EPS:-0.59
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-25.75
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Quince Therapeutics Inc. ( QNCX ) :
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.